Role of k-ras mutations in patients affected with NSCLC and treated with tyrosine kinase inhibitors (tkis): Results of a pooled analysis

14658 Background: The magnitude of survival benefit of TKIs in pts with advanced non small lung cancer (NSCLC) is modest. However, an increasing body of evidence supports a greater survival benefit of TKIs in pts with EGFR mutations, EGFR high copy number and or EGFR overexpression and in females, Asians and non squamous carcinoma. Furthermore, a negative outcome in those pts with K-ras mutations is reported. Methods: We performed a pooled analysis of the most unbiased acknowledges to assess the role of these factors in predicting efficacy of TKIs. An electronic search focused on all phase II and III trials assessing efficacy or activity of TKIs alone or associated with chemotherapy in NSCLC was performed. Evaluable trials had to report at least a subgroup analysis for K ras tests. A pooled analysis was accomplished and Hazard Ratio (HR) with 95% confidence interval was derived for each level of analysed factors. Results: Out of 17 retrieved papers only two were considered for analysis (BR.21, TRIBUTE). P...